Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma With High Tumor Burden-Reference-Cited by-同舟云学术

Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma With High Tumor Burden

Published:2020-01 Issue:1 Volume:43 Page:32-37
ISSN:1524-9557
Container-title:Journal of Immunotherapy
language:en
Short-container-title:

Author:

Qu Changju,Ping Nana,Kang Liqing,Liu Hailing,Qin Songbin,Wu Qian,Chen Xiaochen,Zhou Meng,Xia Fan,Ye Aihua,Kong Danqing,Li Caixia,Yu Lei,Wu Depei,Jin Zhengming

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology,Immunology,Immunology and Allergy

Reference29 articles.

1. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma;Chow;Blood,2018

2. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management;Brudno;Blood Rev,2019

3. Risk classification as the basis for clinical staging of diffuse large-cell lymphoma derived from 10-year survival data;Velasquez;Blood,1989

4. The role of radiotherapy as salvage and/or consolidation treatment in relapsed/refractory and high-risk diffuse large B-cell lymphoma;Grignano;Eur J Haematol,2018

5. Accelerated, but not conventional, radiotherapy of murine B-cell lymphoma induces potent T cell-mediated remissions;Dutt;Blood Adv,2018

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Acute kidney injury following chimeric antigen receptor T-cell therapy: Epidemiology, mechanism and prognosis;Clinical Immunology;2024-09

2. Prevalence of non-Hodgkin lymphoma patients at high-risk of failure after CAR T-cell therapy eligible for bridging radiation therapy;Frontiers in Oncology;2024-08-19

3. CAR-T therapy demonstrated safety and efficacy in relapsed/refractory diffuse large B-cell lymphoma patients complicated with hepatitis B related cirrhosis;2024-08-10

4. CAR T cell combination therapies to treat cancer;Cancer Cell;2024-08

5. Prospects of Synergy: Local Interventions and CAR T Cell Therapy in Solid Tumors;BioDrugs;2024-07-30